SMC unable to recommend bilastine (Ilaxten®) due to non-submission

Source: Scottish Medicines Consortium (SMC)

Date published: 10/08/2011 17:30

Summary
by: Nicola Pocock

The Scottish Medicines Consortium (SMC) is not able to recommend the use of bilastine (Ilaxten®) within NHS Scotland for the symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria, as the holder of the marketing authorisation has not made a submission to SMC.

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.